Sequester
Commercial- Indications
- Soil amendment
Company intelligence / Profile preview
Biodel Inc.
Danbury, Connecticut, United Statesbiodel.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Biodel developed ultra–rapid acting insulins and other diabetes therapies using proprietary formulation technologies. Its lead candidate Linjeta reached NDA review by the FDA but was not approved or commercialized. The company merged with another pharma entity in Boston in May 2016. Most clinical programs are discontinued or pending.
- Therapeutic areas
- Endocrinology
- Modalities
- Peptide drugs (notably insulin and glucagon formulations)Ultra rapid–acting insulin analoguesSublingual tablet formulations (VIAtab)Stabilized glucagon
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical partnerships publicly disclosed prior to merger.
Beyond the preview
Go deeper on Biodel Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biodel Inc..